In this issue of Clinics in Laboratory Medicine, guest editor Dr. Jay Hudgins brings his considerable expertise to the topic of Emerging Considerations in Transfusion Medicine. Top experts explain the new schema by which donors are screened for patients with an overview of the supportive data, challenges of the shrinking donor pool, and what is being done to address this looming shortfall. This issue also provides an overview of all current apheresis procedures, discusses gene therapy products for sickle cell and thalassemia, and offers a look toward the future, including the RMAT program, application of AI in blood donation surveillance, distribution, immunohematology assessment, and in-hospital utilization.
Implementation of the Individual Risk Assessment and Changes to Deferral Periods Since 2020 Expanding the Blood Donor Pool: An Update to Initiatives to Increase New Donor Participation Patient Blood Management and Blood Product Alternatives: An Update Review of Established and Emerging Infectious Diseases in Transfusion Medicine Bacterial Risk Mitigation Strategies for Platelets: Where Are We Now? Pathogen-Reduce Cryoprecipitate: An Overview of Method(s) in Pathogen Reduction, Transfusion-Transmitted Infection Risk, and Inventory Management Considerations An Overview of Common Donor and Therapeutic Apheresis Procedures Emerging Considerations in Transfusion Medicine: Hematopoietic Stem and Progenitor Cell Collection for Gene Therapy for Sickle Cell Disease and Transfusion- Dependent Thalassemia Molecular Testing Expansion and Utilization in Transfusion Medicine The Role of Artificial Intelligence in Transfusion Medicine Disaster Preparedness: Strategies for the Blood Supply
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.
Delivery policy
Security policy
Return policy
